Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros












Base de datos
Intervalo de año de publicación
1.
Expert Rev Anti Infect Ther ; : 1-10, 2024 Jul 09.
Artículo en Inglés | MEDLINE | ID: mdl-38970163

RESUMEN

INTRODUCTION: Antimicrobial peptides (AMPs) are polypeptides with potent antimicrobial activity against a broad range of pathogenic microorganisms. Unlike conventional antibiotics, AMPs have rapid bactericidal activity, a low capacity for inducing resistance, and compatibility with the host immune system. A large body of data supports the antimicrobial activities of a large body of data supports the antimicrobial activities of the class of AMPs known as ß-defensins. This review provides a comprehensive analysis of the effects of ß-defensins against various pathogenic microorganism: bacteria, fungi, viruses, Mycoplasmas and Chlamydiae. The primary mechanisms of ß-defensins against pathogenic microorganisms include inhibition of biofilms formations, dissolution of membranes, disruption of cell walls, and inhibition of adhesion and receptor binding. Although further study and structural modifications are needed, ß-defensins are promising candidates for antimicrobial therapy. AREAS COVERED: This review describes the inhibitory effects of ß-defensins on various pathogenic microorganisms. Additionally, we focus on elucidating the mechanisms underlying their actions to provide, providing valuable references for the further study of ß-defensins. EXPERT OPINION: The biological activities and modes of action of ß-defensins provide powerful resources for clinical microbial infection management. Addressing the salt sensitivity and toxicity of ß-defensins may further enhance their potential applications.

2.
J Colloid Interface Sci ; 670: 486-498, 2024 Sep 15.
Artículo en Inglés | MEDLINE | ID: mdl-38772264

RESUMEN

Establishing a physical barrier between the peritoneum and the cecum is an effective method to reduce the risk of postoperative abdominal adhesions. Meloxicam (MX), a nonsteroidal anti-inflammatory drug has also been applied to prevent postoperative adhesions. However, its poor water solubility has led to low bioavailability. Herein, we developed an injectable hydrogel as a barrier and drug carrier for simultaneous postoperative adhesion prevention and treatment. A third-generation polyamide-amine dendrimer (G3) was exploited to dynamically combine with MX to increase the solubility and the bioavailability. The formed G3@MX was further used to crosslink with poly-γ-glutamic acid (γ-PGA) to prepare a hydrogel (GP@MX hydrogel) through the amide bonding. In vitro and in vivo experiments evidenced that the hydrogel had good biosafety and biodegradability. More importantly, the prepared hydrogel could control the release of MX, and the released MX is able to inhibit inflammatory responses and balance the fibrinolytic system in the injury tissues in vivo. The tunable rheological and mechanical properties (compressive moduli: from âˆ¼ 57.31 kPa to âˆ¼ 98.68 kPa;) and high anti-oxidant capacity (total free radical scavenging rate of âˆ¼ 94.56 %), in conjunction with their syringeability and biocompatibility, indicate possible opportunities for the development of advanced hydrogels for postoperative tissue adhesions management.


Asunto(s)
Dendrímeros , Hidrogeles , Meloxicam , Nylons , Ácido Poliglutámico , Hidrogeles/química , Hidrogeles/farmacología , Animales , Ácido Poliglutámico/química , Ácido Poliglutámico/farmacología , Ácido Poliglutámico/análogos & derivados , Nylons/química , Adherencias Tisulares/prevención & control , Dendrímeros/química , Dendrímeros/farmacología , Meloxicam/química , Meloxicam/farmacología , Meloxicam/administración & dosificación , Ratones , Inflamación/prevención & control , Inflamación/tratamiento farmacológico , Antiinflamatorios no Esteroideos/farmacología , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/administración & dosificación , Ratas , Ratas Sprague-Dawley , Fibrinólisis/efectos de los fármacos , Complicaciones Posoperatorias/prevención & control , Tamaño de la Partícula , Inyecciones , Portadores de Fármacos/química
3.
Expert Rev Anti Infect Ther ; 21(11): 1259-1267, 2023.
Artículo en Inglés | MEDLINE | ID: mdl-37818633

RESUMEN

BACKGROUND: The limited availability of antifungal drugs for candidiasis and the persistent problem of drug resistance, necessitates the urgent development of new antifungal drugs and alternative treatment options. RESEARCH DESIGN AND METHODS: This study examined the synergistic antifungal activity of the combination of eravacycline (ERV) and fluconazole (FLC) both in vitro by microdilution checkerboard assay and in vivo by Galleria mellonella model. The underlying synergistic mechanisms of this drug combination was investigated using RNA-sequencing and qPCR. RESULTS: ERV (2 µg/mL) + FLC (0.25-0.5 µg/mL) had strong synergistic antifungal activity against resistant Candida albicans (C. albicans) in vitro, as evidenced by a fractional inhibitory concentration index of 0.0044-0.0088. In vivo experiments in Galleria mellonella larvae infected with resistant C. albicans revealed that ERV (2 µg/larva) + FLC (1 µg/larva) improved survival rates and reduced fungal burden. The results of RNA-sequencing and qPCR showed that the mechanism of synergistic inhibition on resistant C. albicans was related to the inhibition of DNA replication and cell meiosis. CONCLUSIONS: These results indicate that the combination of ERV and FLC effectively inhibits resistant C. albicans both in vitro and in vivo and lay the foundation for a potential novel treatment option for candidiasis.


Asunto(s)
Candidiasis , Fluconazol , Humanos , Fluconazol/farmacología , Candida albicans , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Sinergismo Farmacológico , Pruebas de Sensibilidad Microbiana , Farmacorresistencia Fúngica , Candidiasis/tratamiento farmacológico , Candidiasis/microbiología , ARN/farmacología , ARN/uso terapéutico
4.
Microbiol Spectr ; 10(3): e0195121, 2022 06 29.
Artículo en Inglés | MEDLINE | ID: mdl-35412374

RESUMEN

Metal chelation is generally considered as a promising antifungal approach but its specific mechanisms are unclear. Here, we identify 13 thiosemicarbazone derivatives that exert broad-spectrum antifungal activity with potency comparable or superior to that of fluconazole in vitro by screening a small compound library comprising 89 thiosemicarbazone derivatives as iron chelators. Among the hits, 19ak exhibits minimal cytotoxicity and potent activity against either azole-sensitive or azole-resistant fungal pathogens. Mechanism investigations reveal that 19ak inhibits mitochondrial respiration mainly by retarding mitochondrial respiratory chain complex I activity through iron chelation, and further reduces mitochondrial membrane potential and ATP synthesis in Candida albicans. In addition, 19ak inhibits fungal ribosome biogenesis mainly by disrupting intracellular zinc homeostasis. 19ak also stimulates the activities of antioxidant enzymes and decreases reactive oxygen species formation in C. albicans, resulting in an increase in detrimental intracellular reductive stress. However, 19ak has minor effects on mammalian cells in depleting intracellular iron and zinc. Moreover, 19ak exhibits low capacity to induce drug resistance and in vivo efficacy in a Galleria mellonella infection model. These findings uncover retarded fungal mitochondrial respiration and ribosome biogenesis as downstream effects of disruption of iron and zinc homeostasis in C. albicans and provide a basis for the thiosemicarbazone 19ak in antifungal application. IMPORTANCE The increasing incidence of fungal infections and resistance to existing antifungals call for the development of broad-spectrum antifungals with novel mechanisms of action. In this study, we demonstrate that a thiosemicarbazone derivative 19ak selectively inhibits mitochondrial respiration mainly by retarding mitochondrial respiratory chain complex I activity through iron chelation and inhibits ribosome biogenesis mainly by disrupting intracellular zinc homeostasis in C. albicans. In addition, 19ak exhibits low capacity to induce fungal resistance, minimal cytotoxicity, and in vivo antifungal efficacy. This study provides the basis of thiosemicarbazone derivative 19ak as a metal chelator for the treatment of fungal infections.


Asunto(s)
Micosis , Tiosemicarbazonas , Animales , Antifúngicos/farmacología , Antifúngicos/uso terapéutico , Azoles/farmacología , Azoles/uso terapéutico , Candida albicans , Farmacorresistencia Fúngica , Hierro/farmacología , Quelantes del Hierro/farmacología , Quelantes del Hierro/uso terapéutico , Mamíferos , Pruebas de Sensibilidad Microbiana , Micosis/tratamiento farmacológico , Respiración , Ribosomas , Tiosemicarbazonas/farmacología , Tiosemicarbazonas/uso terapéutico , Zinc
5.
FEMS Yeast Res ; 21(3)2021 04 07.
Artículo en Inglés | MEDLINE | ID: mdl-33705544

RESUMEN

Amphotericin B (AmB) is a very effective antifungal agent, and resistance in clinical isolates is rare. However, clinical treatment with AmB is often associated with severe side effects. Reducing the administration dose of AmB by combining it with other agents is a promising strategy to minimize this toxicity. In this study, we screened a small compound library and observed that the anti-obesity drug rimonabant exhibited synergistic antifungal action with AmB against Candida species and Cryptococcus neoformans. Moreover, the combination of AmB and rimonabant exhibited synergistic or additive effects against Candida albicans biofilm formation and cell viability in preformed biofilms. The effects of this combination were further confirmed in vivo using a murine systemic infection model. Exploration of the mechanism of synergy revealed that rimonabant enhances the fungicidal activity of AmB by increasing cellular oxidative stress and cell membrane permeability. These findings provide a foundation for the possible development of AmB-rimonabant polytherapies for fungal infections.


Asunto(s)
Anfotericina B/farmacología , Antifúngicos/farmacología , Biopelículas/efectos de los fármacos , Permeabilidad de la Membrana Celular/efectos de los fármacos , Hongos/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Rimonabant/farmacología , Animales , Candida albicans/efectos de los fármacos , Candidemia/tratamiento farmacológico , Criptococosis/tratamiento farmacológico , Cryptococcus neoformans/efectos de los fármacos , Sinergismo Farmacológico , Hongos/clasificación , Masculino , Ratones , Ratones Endogámicos BALB C , Pruebas de Sensibilidad Microbiana , Bibliotecas de Moléculas Pequeñas/farmacología
6.
J Adv Res ; 34: 65-77, 2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-35024181

RESUMEN

Introduction: The increasing morbidity of fungal infections and the prevalence of drug resistance highlighted the discovery of novel antifungal agents and investigation of their modes of action. Iron chelators have been used to treat superficial fungal infections or potentiate the efficacy of certain antifungal drugs. Hinokitiol exhibits potent antifungal activity and iron-chelating ability. However, their relationships have not been established. Objectives: This study aims to explore the selectivity of hinokitiol against fungal cells and mammalian cells and determine the role of iron-chelating for the antifungal activity of hinokitiol. Methods: Iron probe FeRhonox-1 was used to determine intracellular Fe2+ content. 5-Cyano-2,3-ditolyl tetrazolium chloride probe and Cell Counting Kit-8 were used to detect the mitochondrial respiratory activities. Quantitative real-time PCR and rescue experiments were performed to determine the effect of iron on the antifungal activity of hinokitiol. The effects of hinokitiol on fungal mitochondria were further evaluated using reactive oxygen species probes and several commercial Assay Kits. The ability of hinokitiol to induce resistance in Candida species was carried out using a serial passage method. The in vivo therapeutic effect of hinokitiol was evaluated using Galleria mellonella as an infectious model. Results: Hinokitiol was effective against a panel of Candida strains with multiple azole-resistant mechanisms and persistently inhibited Candida albicans growth. Mechanism investigations revealed that hinokitiol chelated fungal intracellular iron and inhibited the respiration of fungal cells but had minor effects on mammalian cells. Hinokitiol further inhibited the activities of mitochondrial respiratory chain complexes I and II and reduced mitochondrial membrane potential, thereby decreasing intracellular ATP synthesis and increasing detrimental intracellular reductive stress. Moreover, hinokitiol exhibited low potential for inducing resistance in several Candida species and greatly improved the survival of Candida-infected Galleria mellonella. Conclusions: These findings suggested the potential application of hinokitiol as an iron chelator to treat fungal infections.


Asunto(s)
Candida albicans , Hierro , Animales , Pruebas de Sensibilidad Microbiana , Mitocondrias , Monoterpenos , Respiración , Tropolona/análogos & derivados
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...